BACKGROUND: In humans, ghrelin has been found to stimulate appetite while PYY3-36 to reduce it; these orexigenic and anorexigenic peptides play significant roles in appetite control. We investigated pre- and postprandial responses of ghrelin and PYY in anorexia nervosa (AN) and the influence of weight gain. METHODS: Plasma ghrelin, PYY3-36, glucose and insulin responses after ingestion of a 400 kcal standard meal were measured in 14 patients with restricting type of AN and 12 controls. The AN patients were evaluated before therapy and after inpatient therapy. Psychometry was performed by the use of Eating Disorders Inventory. RESULTS: Ghrelin was suppressed during the meal test, while PYY3-36 was increased in all of the groups. Before therapy, AN patients had significantly increased levels of ghrelin and PYY3-36 compared to the control (P<0.01). After therapeutic intervention, as the nutritional status of AN patients improved, the secretion of these hormones were increased (P<0.05), but not normalized as in psychological testing. In contrast, insulin and glucose responses were normalized after inpatient therapy. CONCLUSIONS: We found that both ghrelin and PYY3-36 increased in AN patients and these changes were not normalized in contrast to insulin after treatment. The increase in both orexigenic ghrelin and anorexigenic PYY3-36 may have a role in pathological eating behavior in AN.
BACKGROUND: In humans, ghrelin has been found to stimulate appetite while PYY3-36 to reduce it; these orexigenic and anorexigenic peptides play significant roles in appetite control. We investigated pre- and postprandial responses of ghrelin and PYY in anorexia nervosa (AN) and the influence of weight gain. METHODS: Plasma ghrelin, PYY3-36, glucose and insulin responses after ingestion of a 400 kcal standard meal were measured in 14 patients with restricting type of AN and 12 controls. The AN patients were evaluated before therapy and after inpatient therapy. Psychometry was performed by the use of Eating Disorders Inventory. RESULTS:Ghrelin was suppressed during the meal test, while PYY3-36 was increased in all of the groups. Before therapy, AN patients had significantly increased levels of ghrelin and PYY3-36 compared to the control (P<0.01). After therapeutic intervention, as the nutritional status of AN patients improved, the secretion of these hormones were increased (P<0.05), but not normalized as in psychological testing. In contrast, insulin and glucose responses were normalized after inpatient therapy. CONCLUSIONS: We found that both ghrelin and PYY3-36 increased in AN patients and these changes were not normalized in contrast to insulin after treatment. The increase in both orexigenic ghrelin and anorexigenic PYY3-36 may have a role in pathological eating behavior in AN.
Authors: Laura A Berner; Tiffany A Brown; Jason M Lavender; Emily Lopez; Christina E Wierenga; Walter H Kaye Journal: Mol Cell Endocrinol Date: 2018-11-02 Impact factor: 4.102
Authors: Elizabeth A Lawson; Kamryn T Eddy; Daniel Donoho; Madhusmita Misra; Karen K Miller; Erinne Meenaghan; Janet Lydecker; David Herzog; Anne Klibanski Journal: Eur J Endocrinol Date: 2010-11-23 Impact factor: 6.664
Authors: Laura M Holsen; Elizabeth A Lawson; Kara Christensen; Anne Klibanski; Jill M Goldstein Journal: Psychiatry Res Date: 2014-05-06 Impact factor: 3.222
Authors: O Giménez-Palop; R Coronas; J Cobo; L Gallart; J D Barbero; I Parra; G Fusté; J Vendrell; M Bueno; J M González-Clemente; A Caixàs Journal: J Endocrinol Invest Date: 2011-12-15 Impact factor: 4.256
Authors: Christopher Mancuso; Alyssa Izquierdo; Meghan Slattery; Kendra R Becker; Franziska Plessow; Jennifer J Thomas; Kamryn T Eddy; Elizabeth A Lawson; Madhusmita Misra Journal: Psychoneuroendocrinology Date: 2019-12-23 Impact factor: 4.905
Authors: Kamryn T Eddy; Elizabeth A Lawson; Christina Meade; Erinne Meenaghan; Sarah E Horton; Madhusmita Misra; Anne Klibanski; Karen K Miller Journal: J Clin Psychiatry Date: 2015-01 Impact factor: 4.384